Cargando…
Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy
BACKGROUND: Empagliflozin, a sodium–glucose co-transporter 2 inhibitor (SGLT2i), has been reported to significantly reduce the risk of heart failure in multiple clinical studies. However, the underlying mechanisms remain elusive. This study aimed to investigate the effect of empagliflozin on branche...
Autores principales: | Zhang, Lin, Zhang, Heming, Xie, Xiuzhu, Tie, Ruping, Shang, Xiaolin, Zhao, Qianqian, Xu, Junjie, Jin, Liyuan, Zhang, Jinying, Ye, Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163822/ https://www.ncbi.nlm.nih.gov/pubmed/37149696 http://dx.doi.org/10.1186/s13098-023-01061-6 |
Ejemplares similares
-
Berberine induces autophagy in glioblastoma by targeting the AMPK/mTOR/ULK1-pathway
por: Wang, Jiwei, et al.
Publicado: (2016) -
Inhibition of mTOR or MAPK ameliorates vmhcl/myh7 cardiomyopathy in zebrafish
por: Bu, Haisong, et al.
Publicado: (2021) -
Xiaojianzhong decoction attenuates aspirin-induced gastric mucosal injury via the PI3K/AKT/mTOR/ULK1 and AMPK/ULK1 pathways
por: Chen, Ting, et al.
Publicado: (2023) -
The Ameliorative Effect of Empagliflozin in Vigabatrin-Induced Cerebellar/Neurobehavioral Deficits: Targeting mTOR/AMPK/SIRT-1 Signaling Pathways
por: Amer, Rabab M., et al.
Publicado: (2022) -
Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
por: Ma, Yuting, et al.
Publicado: (2022)